Table 2.
Events During Hospitalization, Interventions, and Outcomes
| Hospitalized (N = 1,483) | |
|---|---|
| Coinfections* | |
| Positive influenza | 54 (3.6) |
| Positive RSV | 3 (0.2) |
| Complications* | |
| Positive blood culture | 116 (13.2) |
| Positive sputum culture | 184 (97.4) |
| Cardiac dysrhythmias | 142 (9.6) |
| Developed bacterial pneumonia | 68 (4.6) |
| Developed ARDS | 265 (17.9) |
| Developed rhabdomyolysis (CK ≥ 1,000) | 38 (8.7) |
| Interventions | |
| High‐flow nasal cannula | 1,131 (76.3) |
| CPAP/BPAP | 197 (13.3) |
| Prone positioning | 222 (15.0) |
| Inhaled pulmonary vasodilators | 99 (6.7) |
| ECMO | 13 (0.9) |
| Vasopressors | 71 (4.8) |
| Steroids | 676 (45.6) |
| Lopinavir/ritonavir | 15 (1.0) |
| Hydroxychloroquine | 345 (23.3) |
| Remdesivir | 136 (9.2) |
| Tocilizumab | 152 (10.2) |
| Outcomes | |
| Hospital length of stay (days) | 5 (2–9) |
| ICU length of stay (days) | 5.1 (1.9–13.5) |
| Intubated patients | 282 (19.0) |
| Days of mechanical ventilation | 10 (5–17) |
Data are reported as n (%) or median (IQR).
ARDS = acute respiratory distress syndrome; BPAP = bilevel positive airway pressure; CPAP = continuous positive airway pressure; ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit.
*
Not all patients received these studies (percentages reflect the number with a given finding divided by the total labs performed in this population).